Sargent Bickham Lagudis’s Acadia Pharmaceuticals ACAD Stock Holding History

Sargent Bickham Lagudis’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-100	Closed	-$5K	–	928
2020 Q4	$5K	Buy	+100	New	+$4.96K	﹤0.01%	729
2017 Q1	–	Sell	-256	Closed	-$7K	–	747
2016 Q4	$7K	Hold	256	–	–	﹤0.01%	594
2016 Q3	$8K	Hold	256	–	–	﹤0.01%	594
2016 Q2	$8K	Hold	256	–	–	﹤0.01%	566
2016 Q1	$7K	Buy	+256	New	+$5.58K	﹤0.01%	599

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sargent Bickham Lagudis's ACAD Position: Q1 2021 in Review

Sargent Bickham Lagudis sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 100 shares — an estimated $5K sold.

Sargent Bickham Lagudis first reported a position in ACAD in Q1 2016 and held it in 5 quarters. The position peaked at $8K in Q3 2016. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

Sargent Bickham Lagudis reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Sargent Bickham Lagudis sold 100 Acadia Pharmaceuticals shares in Q1 2021, an estimated $5K.
Sargent Bickham Lagudis first reported a position in Acadia Pharmaceuticals in Q1 2016 and held it in 5 quarters.
Sargent Bickham Lagudis's Acadia Pharmaceuticals position peaked at $8K in Q3 2016.
272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q1 2021, filed 24 May 2021.